Patent IE-37313-B1 (IE)
Title: Antibiotic and process for its production
IPC: C07G11/00
Filed: 1973-02-21
Abstract: 1369179 Aza-steroidal antibiotics A-25822 ELI LILLY & CO 16 Feb 1973 [29 Feb 1972 2 Feb 1973] 7805/73 Heading C2A Novel antibiotic substances having an azasteroid structure and designated generally as A-25822 antibiotics are produced by cultivating Geatrichium flavo-brunneum NRRL 3862 under submerged aerated conditions in an aqueous nutrient medium containing assimilable sources of carbon, nitrogen and inorganic salts until a substantial amount of antibiotic activity is present in said medium, and then recovering the said antibiotics therefrom. The individual antibiotic compounds, factors A, B, D, H, L, M and N are then isolated from the resulting mixture, or alternatively separately isolated from the fermented broth. A-25822-A, B and M have the general Formula (I) wherein for factor A, R 1 and R 2 are each methy and R 3 is hydroxy; for factor B, R 1 and R 2 are each hydrogen and R 3 is acetoxy; and for factor M, R 1 and R 2 are each hydrogen and R 3 is hydroxy. Factor N has the formula Accordingly using the homosteroidal nomenclature system in which " 14a " is used to designate the ring enlarging atom, factor A is 3# - hydroxy - 24 - methylene - 14a - aza - D- homo - 4,4 - dimethyl - 5 - α - cholest - 8(9),14- (14a) - diene; Factor B is 3# - hydroxy - 24- methylene - 14a - aza - D - homo - 5α - cholest - 8- (9),14(14a)-diene; and factor M (the acetate of factor B) is 3#-acetoxy-24-methylene-14a-aza-D- homo - 5α - cholest - 8(9),14(14a) - diene. Factor N is 24-methylene-14a-aza-D-homo-5α-cholest-8- (9),14(14a)-dien-3-one. The factors D, L and H are mainly characterized and defined by their physico-chemical characteristics since their structures have not definitely been determined. However factor D is preferably a 15-hydroxy substituted factor B, namely 3,15-dihydroxy-24-methylene-14a-aza- D - homo - 5α - cholest - 8(9),14(14a) - diene, and factor L is probably a 15-keto derivative of factor B, namely 3#-hydroxy-24-methylene-14aaza - D - homo - 5α - cholest - 8(9),14(14a) - diene- 15-one. Factor D is a white amorphous compound, melting at 51-55‹ C., having amolecular weight of 427 and an empirical formula: C 28 H 45 NO 2 , a specific rotation [α]<SP>25</SP> D = +39 degrees (C = 0À725 MeOH), a U.V. absorption maximum, #max at 235 mÁ in EtOH and at 270 mÁ in acid. Factor L is a yellowish amorphous compound having a molecular weight of 425 and an empirical formula: C 28 H 43 NO 2 , a specific rotation [α]<SP>25</SP> D = +75 degrees (C = 0À072, MeOH), a U.V. absorption maximum, #max at 262 mÁ in basic and neutral solution and at 279 mÁ in acid. Factor H is a white amorphous compound melting at 74-77‹ C., having a molecular weight of 425 and an empirical formula: C 28 H 43 NO 2 , a specific rotation [α]<SP>25</SP> D = +15 degrees (C = 0À147, MeOH), a U.V. absorption maximum, #max at 235 mÁ in basic and neutral solution and at 270 mÁ in acid. The compounds containing hydroxyl groups can be converted to their acetate esters by treatment with acetic anhydride in pyridine. For example factors A, B and L form mono-acetyl derivatives, and factor D forms a diacetyl derivative; factor B monoacetate is identical with factor M (i.e. R 1 = R 2 = H, R 3 = acetoxy, in the above Formula I). All of the compounds form acid-addition salts with organic and inorganic salts and react with methyl iodide to form crystalline methiodide salts. Factor B as the free base exhibits polymorphism (probably due to different diastereoisomeric forms) when crystallized from different solvents; e.g. melting points of 56-58‹ C., 42-44‹ C. and 115-118‹ C., with differing X-ray diffraction patterns, when crystallized from n-hexane, pentane and an acetone-hexane mixture respectively. The antibiotics are recovered from the culture broth, mainly from the mycelium, by extraction with an organic solvent (e.g. ethyl acetate), purified by conventional washing and backextraction procedures, and the individual components are then separated by column chromatography and fractional crystallization. They may be used with a suitable carrier or diluent in antibiotically active pharmaceutical compositions and in disinfectant compositions.
[GB1369179A]